|
Oct 9
|
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...
|
|
Aug 5
|
Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?
|
|
Jul 24
|
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
|
|
Jun 17
|
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
|
|
Jun 13
|
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
|
|
May 15
|
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 15
|
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
|
|
May 14
|
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
|
May 7
|
Syros to Participate in Upcoming Investor Conferences
|
|
May 7
|
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
|
|
May 2
|
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
|
|
May 1
|
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 12
|
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
|
|
Apr 10
|
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
|
|
Apr 10
|
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
|
|
Apr 9
|
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
|
|
Apr 2
|
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 28
|
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
|
|
Mar 27
|
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
|